News

MEMO THERAPEUTICS AG APPOINTS PAUL CARTER AS CHAIRPERSON

Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma...

read more

LimmaTech Appoints Staph Leavenworth Bakali as Chairman of the Board

Schlieren (Zurich), 1 July 2024 - LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced the appointment of Staph Leavenworth Bakali as independent Chairman of its Board of Directors. Mr. Leavenworth Bakali brings over 30 years of senior executive and board-level experience...

read more

Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft

Schlieren (Zurich), Switzerland, June 25, 2024 – Kuros Biosciences, a leader in next generation bone healing technologies, today announced the publication of a peer-reviewed manuscript that details the clinical data of its MAXA Level 1 prospective, multi-center, randomized, intra-patient controlled clinical study in Spine1. Published clinical results of "Efficacy of Biphasic...

read more